A Phase 4 interventional study of Paricalcitol in Nephropathy, sponsored by Effice Servicios Para la Investigacion S.L.. Terminated. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-02-26.
Sponsored by Effice Servicios Para la Investigacion S.L. · Phase 4, Interventional, and Treatment
To provide evidence based prospectives of the potential benefit effects of paricalcitol, an analog of vitamin D, over the prevention / retardation of the progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.
Providing prospective results based on evidence of potential beneficial effects of paricalcitol, an analogue of vitamin D in the prevention / delay of progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.
3,840 studies on the registry are indexed under Kidney Diseases; 500 are open to participants now.
This study's enrollment of 50 is below the median of 70 across 2,640 interventional studies indexed under Kidney Diseases.
Browse Kidney Diseases studies →This is the only study on the registry with Effice Servicios Para la Investigacion S.L. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patient will take one pill of paricalcitol a day.
Drug: Paricalcitol
Patient allocated to this arm will only take his/her habitual treatment
Also known as: Zemplar- 1 ug/day
Prevention on vessels progression based on paricalcitol intake.
Providing prospective results based on evidence of potential beneficial effects of paricalcitol, an analogue of vitamin D in the prevention / delay of progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.
Time frame: participants will be followed for the duration of whole study, an expected average of 1 year
No study locations are listed for this record.
This study is terminated, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.